Northwestern Medicine explicitly includes off-label treatment among the approaches its menopause program may consider. That term can be misunderstood as a product category. It describes a use, while the identity and regulatory status of the medicine remain separate questions.
This September 29, 2026 review examines Northwestern’s program and Chicago location with FDA explanations of those distinctions. The service is verified, but its reviewed pages do not confirm an oral progesterone manufacturer, a compounded formula or an individual patient’s treatment.
In this article
A program offering several approaches
Northwestern’s Program for Menopause describes hormonal, nonhormonal and other treatment approaches. It also discusses care for people whose medical histories complicate treatment decisions. This establishes an actual menopause clinical offering, rather than a page that merely explains what menopause is. It does not establish that a particular approach will be appropriate after assessment.
The Mount Sinai review considers a shorter service description with fewer treatment details. The comparison is useful for understanding what the public record explains, not for ranking clinical outcomes. Northwestern’s longer list of options does not prove that a reader needs more treatment, or that oral progesterone is included in every proposed plan.
Off-label refers to how an approved medicine is used
FDA explains that an off-label use can involve a condition, route or other use that has not been approved for the medicine. That is different from saying that the product itself has no approval. FDA has not established the safety and effectiveness of the unapproved use merely because the medicine is approved for another purpose.
Northwestern’s mention of the category therefore raises a precise discussion: what actual use is proposed, and what supports it? The service page does not specify an off-label oral progesterone regimen. Our medicine-purpose guide helps separate that question from the much broader statement that a program offers individualized menopause care.
Compounding is a separate regulatory distinction
A compounded preparation is not simply another name for an approved medicine used off-label. FDA describes compounded drugs as products that do not undergo its premarket approval process, while recognizing circumstances in which compounding can meet medical needs. These distinctions should remain separate even when both arise in hormone discussions.
The reviewed Northwestern pages do not establish that a particular patient will receive a compounded product. Nor does the word “alternative” identify a formula or establish its safety. A clear explanation would name the proposed medicine and then address its intended use and regulatory status. This review does not infer a compounding service from a broad list of menopause approaches.
A named oral label offers a different level of detail
The Prometrium label identifies oral micronized progesterone and specific uses. Its ingredient record includes peanut oil and a peanut-allergy contraindication. Those details belong to that labeled product, not to Northwestern’s program as a whole. There is no basis in the reviewed clinic pages for assuming Prometrium is the product that would be prescribed.
The capsule excipients guide explains why a drug’s active ingredient does not fully identify its formulation. A pharmacist’s check of the actual product and a clinician’s assessment of the relevant history are necessary parts of an individual discussion. Neither “off-label” nor “bioidentical” supplies the ingredient list, route or patient-specific safety conclusion.
Intake materials are information, not approval
The program describes contact with a coordinator and completion of a questionnaire before the first visit. The program page connects those steps to arranging and preparing for care. Sending information does not establish that a prescription will be issued, and the coordinator’s role should not be confused with a clinician’s evaluation.
The UCLA Health review offers a useful comparison because its patient information also describes advance questionnaires. Both illustrate preparation, without turning a completed form into eligibility for a medicine. The eventual clinical conversation still needs to establish what concern is being addressed and whether a specific treatment is appropriate.
The location record is not a travel or prescription guarantee
Northwestern identifies its Center for Sexual Medicine and Menopause in Chicago. The center’s location page provides practical access information and links to its services. Institutional assistance with a visit should not be read as nationwide telemedicine, a medicine-delivery service or an assurance that any requested treatment will be offered.
The reviewed records do not quote an all-inclusive oral progesterone plan. A visit, additional assessment and a future prescription may have different financial responsibilities that require confirmation. Comparing a location’s logistical convenience with an online clinic can be useful, but it cannot supply a missing product price, insurance decision or refill arrangement. Those are separate questions for the actual encounter.
Keep the rationale and the response plan together
If a clinician proposes an unapproved use of an approved medicine, the explanation should make the intended benefit and uncertainties understandable. FDA’s off-label discussion supports asking about the rationale; it does not direct a reader to seek a particular use. Prometrium’s current label also retains warnings and contraindications, including dizziness and drowsiness concerns.
The follow-up guide focuses on who will answer questions after a treatment decision. Northwestern’s program can be assessed as a real specialty service with a broad stated approach. The particular oral formulation, its proposed use, individual suitability and the plan for later concerns remain matters for the treating professionals, not conclusions of this review.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Northwestern Medicine — Program for MenopauseOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29
- FDA — Understanding Unapproved Use of Approved Drugs: Off LabelFederal primary drug-label or regulatory information; applies only within the stated product and regulatory scope. · Checked 2026-09-29
- FDA — Understanding the Risks of Compounded DrugsFederal primary drug-label or regulatory information; applies only within the stated product and regulatory scope. · Checked 2026-09-29
- DailyMed — Prometrium progesterone capsule, Acertis Pharmaceuticals LLCCurrent exact oral Prometrium DailyMed label, updated July 23, 2026; patient leaflet revision February 2026. Does not establish provider supply. · Checked 2026-09-29
- Northwestern Medicine — Center for Sexual Medicine and Menopause, ChicagoOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29